Plasmid BMP-2–embedded gelatin sponge as a gene-activated matrix for preosteoblast differentiation

Hsieh, Ming-Kai; Toh, Elsie Khai-Woon; Tsai, Tsung-Ting; Niu, Chi‐Chien; Wu, Shinn-Chih; Lai, Po‐Liang

doi:10.1016/j.jddst.2019.101129

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mouse preosteoblast cell line MC3T3-E1 21 , 22 was cultured in minimum essential medium-alpha (MEM-α) (Gibco) supplemented with 10% FBS (Gibco) and antibiotic solution (100 U/mL penicillin and 100 μg/mL streptomycin). The cells were maintained at 37°C in a humidified incubator supplied with 5% CO 2 .…”

Section: Methodsmentioning

confidence: 99%

Local application of zoledronate inhibits early bone resorption and promotes bone formation

Hsieh,

Wang,

Kao

et al. 2024

JBMR Plus

View full text Add to dashboard Cite

Nonunion resulting from early bone resorption is common after bone transplantation surgery. In these patients, instability or osteoporosis causes hyperactive catabolism relative to anabolism, leading to graft resorption instead of fusion. Systemic zoledronate administration inhibits osteoclastogenesis and is widely used to prevent osteoporosis; however, evidence on local zoledronate application is controversial due to osteoblast cytotoxicity, uncontrolled dosing regimens, and local release methods. We investigated the effects of zolendronate on osteoclastogenesis and osteogenesis and explored the corresponding signaling pathways. In vitro cytotoxicity and differentiation of MC3T3E1 cells, rat bone marrow stromal cells (BMSCs) and preosteoclasts (RAW264.7 cells) were evaluated with different zolendronate concentrations. In vivo bone regeneration ability was tested by transplanting different concentrations of zolendronate with β-TCP bone substitute into rat femoral critical-sized bone defects. In vitro, zolendronate concentrations below 2.5 × 10-7 M did not compromise viability in the three cell lines and did not promote osteogenic differentiation in MC3T3E1 cells and BMSCs. In RAW264.7 cells, zoledronate inhibited ERK and JNK signaling, downregulating c-Fos and NFATc1 expression, with reduced expression of fusion-related DC-STAMP and osteoclast-specific Ctsk and TRAP. In vivo, histological staining revealed increased osteoid formation and neovascularization and reduced fibrotic tissue with 500 μM and 2000 μM zolendronate. More osteoclasts were found in the normal saline group after 6 weeks, and sequential osteoclast formation occurred after zoledronate treatment, indicating inhibition of bone resorption during early callus formation without inhibition of late-stage bone remodeling. In vivo, soaking β-TCP artificial bone with 500 μM or 2000 μM zoledronate is a promising approach for bone regeneration, with potential applications in bone transplantation.

show abstract

Section: Methodsmentioning

confidence: 99%